RHEUMATOLOGY, vol.51, no.5, pp.910-914, 2012 (Journal Indexed in SCI)
Article / Article
Title of Journal :
ankylosing spondylitis, anti-TNF-alpha, pulse wave velocity, arterial stiffness, cardiovascular burden, NECROSIS FACTOR AGENTS, PULSE-WAVE VELOCITY, ANKYLOSING-SPONDYLITIS, ENDOTHELIAL FUNCTION, CARDIOVASCULAR EVENTS, RHEUMATOID-ARTHRITIS, DISEASE-ACTIVITY, INFLIXIMAB, ATHEROSCLEROSIS, INFLAMMATION
Objective. The availability of new-generation drugs has provided significant success reflected by disease activity markers and clinical status in AS, but controversial reports necessitate further assessment of associated increased risk of cardiovascular burden that might persist. Hence this prospective clinical study evaluated the effectiveness of a 24-week anti-TNF-alpha therapy on vascular stiffness [pulse wave velocity (PWV)] in AS.